What the 36-month data actually show

Published clinical follow-up data from the Jerosch et al. prospective Post-Market Clinical Follow-up (PMCF) study — the primary dataset cited in the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025) — record a mean IKDC improvement of 32.4 points at 36 months, with patients reaching an absolute score of 80.1 out of 100.

To understand what that number means in practice: the International Knee Documentation Committee questionnaire sets a Minimal Clinically Important Difference (MCID) of 16.7 points — the minimum change a patient is likely to notice as real improvement in daily function. At 36 months, the cohort's mean gain is roughly double that threshold. In other words, the benefit recorded at three years is not a marginal statistical signal; it sits well above the level most patients would experience as meaningful.

Unlike hyaluronic acid viscosupplementation, which typically requires repeat courses approximately every six months, ChondroFiller is designed as a single-course treatment. The collagen scaffold is placed once under ultrasound guidance; the subsequent process of cell migration and tissue maturation unfolds over the months that follow, without further injections.

These figures describe outcomes from one prospective cohort — a single patient population followed over time — and should be read in that light rather than as a universal guarantee.

Do gains hold or fade after the first year?

The short answer is that gains do not fade. Comparing the 36-month IKDC improvement of 32.4 points with the mean improvement recorded across four independent prospective knee cohorts at 12 months — approximately 30 points — shows a trajectory that is stable to slightly improving, not regressing. The three-year figure is marginally higher than the one-year figure, which is the opposite of what would be expected if the repair were breaking down.

A common source of confusion is the relationship between the scaffold's lifespan and the durability of the benefit. These are two separate timelines. The collagen matrix is progressively resorbed and replaced by the patient's own repair tissue over roughly 12 to 24 months, a process initiated by cell migration into the scaffold in the early weeks after injection. What remains after that resorption is complete is not a void but the body's own regenerated tissue. Symptom durability at three years therefore reflects the quality of that biological repair — not the continued presence of the original scaffold material. Think of it as a temporary framework whose job is finished once the new tissue has taken hold.

The marginal increase between 12 and 36 months is consistent with that picture: repair tissue may continue to consolidate into the second and third year as the scaffold gradually clears. This finding comes from a single prospective cohort, and independent replication over a three-year timeframe is not yet available, so the trajectory should be read as encouraging rather than definitive.

What MRI shows about the repair tissue

MRI imaging offers a structural window into what is actually happening inside the treated joint — independent of how a patient rates their symptoms. Published MOCART scoring data show the defect filling progressively over the first year: in one tracked cohort the score rises from 65.3 at four weeks to 81.6 by twelve months, a trajectory that reflects the scaffold gradually giving way to maturing repair tissue rather than any sudden transformation.

Across European knee cohorts, twelve-month MOCART scores cluster between 81.6 and 84.3 — a range that indicates more than 80% of the defect has been filled with tissue that integrates well with the surrounding native cartilage. The wording matters here: published data describe this as repair tissue integrating with the adjacent cartilage surface, which is a more measured characterisation than full cartilage regeneration — and it is this structural picture that aligns with the sustained functional gains discussed in the preceding sections.

Laboratory evidence adds a mechanistic dimension without overstating the clinical picture. A 2025 ex vivo study recorded a 2.4-fold increase in DNA content within the ChondroFiller scaffold by day 14 post-treatment — direct evidence of active cell migration into the collagen matrix in the early post-injection period. This is a bench finding rather than a clinical outcome, but it corroborates the biological timeline that the MRI data trace at the joint level: cells move in early, and structural filling consolidates over the months that follow.

Evidence from hip and wrist studies

Knee data form the backbone of this article, but two independent peer-reviewed cohorts from other joints add meaningful weight to the overall durability picture.

In a prospective hip arthroscopy series, Mazek et al. (2021, PMC8460160) followed 26 adults with acetabular cartilage lesions larger than 2 cm² for between 12 and 60 months. Of the 21 patients evaluable at three to five years, 17 achieved good or excellent MRI outcomes — a proportion consistent with the 70–85% patient success range reported across joint types. The caveat is instructive: patients with pre-existing osteoarthritis classified as Tönnis grade 2 or 3 — an imaging-based scale on which grade 2 indicates moderate and grade 3 severe established arthritic change — had poor results, reinforcing that ChondroFiller is suited to focal defects rather than advanced joint-wide disease.

The 2025 wrist study by Demmer et al. (PMC12498443, n=25 treated) extends the evidence to small joints. At follow-up arthroscopy, the ChondroFiller group showed significantly better cartilage quality than controls (median Outerbridge 1.5 versus 3, P=0.006; ICRS grade 1 versus 3, P=0.002). Flush application produced no fibrous tissue formation.

Neither cohort replicates the three-year knee IKDC dataset, but taken alongside it, published independent cohorts indicate that the durability signal is not confined to a single joint or a single investigator group.

How this compares with shorter-acting treatments

Hyaluronic acid injections work by supplementing the joint's natural lubricating fluid, offering symptomatic relief that published evidence suggests typically lasts in the region of a few months before the benefit diminishes and a repeat course is needed — roughly every six months for patients who respond. That palliative role is clinically legitimate, but viscosupplementation does not modify the underlying structural deficit, and evidence on whether it alters disease course remains limited.

Corticosteroid injections occupy a similarly defined niche: useful for managing acute inflammation and providing short-term pain relief, generally measured in weeks to a few months, but without a mechanism for repairing the cartilage surface. For a patient dealing with an acute flare or requiring pain control ahead of a procedure, corticosteroid has an established clinical place — it simply operates over a different timeframe and at the symptom rather than structural level.

ChondroFiller is designed differently. As a single-course injectable collagen scaffold, the intent is biological repair of the focal defect rather than repeated symptom management. The scaffold is resorbed over roughly one to two years and replaced by the patient's own repair tissue — so the treatment effect, where it occurs, is tied to structural changes that should, in principle, not require topping up.

The important caveat is that this comparison rests on mechanism differences and separate study populations, not head-to-head trial data. No published randomised controlled trial has directly compared ChondroFiller with hyaluronic acid or corticosteroid at 36 months, so any characterisation of relative benefit is based on how the three treatments work rather than how they perform against each other in the same patient group.

Who this evidence applies to — and where it has limits

The evidence summarised here comes from a single prospective Post-Market Clinical Follow-up cohort — the Jerosch et al. study underlying CER Version 09 (April 2025). PMCF studies are rigorous observational designs, but they lack a parallel control group; independent replication of the 36-month IKDC figure, and head-to-head RCT comparisons at the three-year mark, are not yet published. That gap does not invalidate the findings, but it is the appropriate frame for interpreting them.

Patient selection is central to who the evidence most directly applies to. The hip cohort (Mazek et al. 2021, PMC8460160) made explicit what the knee data imply: patients with pre-existing osteoarthritis classified as Tönnis grade 2 or 3 — indicating moderate to severe generalised arthritic change across the joint — had poor results. ChondroFiller is designed for focal cartilage defects in a joint that is otherwise in reasonable health; it is not positioned as a treatment for advanced joint-wide disease, and published guidance reflects that distinction.

Geographically, the device holds CE marking and is used across Europe. It is not FDA-approved, so the clinical evidence cited in this article reflects CE-marked practice rather than a globally applicable regulatory setting.

On safety, published series report an adverse device effect rate approaching zero across thousands of applications. Where fibrous tissue formation has been documented, the literature attributes this to overfilling technique rather than the scaffold itself; flush placement in the wrist study produced no such complications.

Taken together, the published data present a consistent picture for a specific patient profile — focal defect, no advanced generalised OA, CE-marked geography — and a more uncertain one outside those parameters. Individual defect type, grade, and broader joint health are the variables that determine fit, and those require clinical assessment rather than inference from population-level outcomes.